Navigation Links
Novocell Appoints Orville G. Kolterman, M.D. to Board of Directors

SAN DIEGO, Oct. 25 /PRNewswire/ -- Novocell, Inc., a leading stem cell engineering company, today announced the appointment of Orville G. Kolterman, M.D., Senior Vice President, Clinical & Regulatory Affairs of Amylin Pharmaceuticals, to the company's Board of Directors.

Dr. Kolterman joined Amylin in 1992 and has served as Senior Vice President, Clinical Affairs since February 1997 until present and as Senior Vice President, Regulatory Affairs since August 2005. At Amylin, Dr. Kolterman has been instrumental in the development of the company's first-in-class diabetes medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection.

"Dr. Kolterman's breadth of experience, including the clinical development of successful diabetes therapeutics, will be invaluable to Novocell as we advance the development of our diabetes cell therapy and additional cell therapies," said Alan J. Lewis, President, Chief Executive Officer and Director of Novocell.

"I am pleased to join the Novocell board and look forward to working with the Company to help advance it's innovative platform technologies, including its human embryonic stem cell engineering, cell encapsulation and drug discovery efforts, which hold promise for the treatment of a range of chronic diseases," said Dr. Kolterman.

Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California, San Diego (UCSD) Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a member of the Epidemiology of Diabetes Intervention and Complications Study. He is also a past-president of the California Affiliate of the American Diabetes Association. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

About Novocell

Novocell is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies to treat diseases including diabetes. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell is focused on the development of a variety of technology platforms including stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999 and merged with CyThera, Inc. and BresaGen, Inc. in 2004. For more information, visit

Media Contact:

Julie Rathbun

Rathbun Communications, Inc.

(206) 769-9219

SOURCE Novocell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... June 1, 2016 Favorable Government ... Administration and Criminal Identification to Boost Global Biometrics System ... released TechSci Research report, " Global Biometrics Market ... Forecast and Opportunities, 2011 - 2021", the global biometrics ... 2021, on account of growing security concerns across various ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
Breaking Biology News(10 mins):